Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yoshiaki Rai"'
Autor:
Kentaro Tamaki, Keely May McNamara, Yasuyo Ohi, Saki Nakagawa, Yoshiaki Rai, Minoru Miyashita, Hironobu Sasano, Katsuhiko Ono, Yasuaki Sagara, Takanori Ishida, Hisashi Hirakawa, Noriaki Ohuchi, Fouzia Guestini
Publikováno v:
Breast Cancer Research and Treatment. 173:275-288
Triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy (NAC) harbor higher risk of relapse, and eventual demise compared to those who achieve pathologic complete response. Therefore, in this study, we a
Autor:
Yoshiaki Rai, Minoru Miyashita, Hisashi Hirakawa, Mika Watanabe, Yayoi Takahashi, Saki Nakagawa, Hironobu Sasano, Yasuhiro Miki, Shuko Hata, Yasuaki Sagara, Kentaro Tamaki, Noriaki Ohuchi, Yasuyo Ohi, Takashi Suzuki, Takanori Ishida
Publikováno v:
Breast Cancer Research and Treatment. 155:65-75
Invasive ductal and lobular carcinomas (IDC and ILC) are the two most common histological types of breast cancer, and have been considered to develop from terminal duct lobular unit but their molecular, pathological, and clinical features are markedl
Autor:
Keely May McNamara, Kentaro Tamaki, Yasuyo Ohi, Yasuhiro Miki, Yasuaki Sagara, Mayu Takagi, Tomomi Yoda, Hironobu Sasano, Yoshiaki Rai, Hisashi Hirakawa, Takashi Suzuki, Takanori Ishida, Noriaki Ohuchi
Publikováno v:
Cancer Science
Invasive lobular carcinoma (ILC) accounts for approximately 10% of all breast carcinomas and is characterized by higher levels of androgen receptor (AR) compared to invasive ductal carcinoma (IDC). Despite this potentially androgen-responsive environ
Autor:
Kentaro Tamaki, Yasuyo Ohi, Yoshiaki Rai, Shuko Hata, Minoru Miyashita, Yasuaki Sagara, Mayu Takagi, Hisashi Hirakawa, Takashi Suzuki, Takanori Ishida, Tomomi Yoda, Hironobu Sasano, Noriaki Ouchi, Yasuhiro Miki
Publikováno v:
Breast cancer research and treatment. 156(1)
The great majority of invasive lobular carcinoma (ILC) is estrogen-dependent luminal A type carcinoma but the details of estrogen actions and its intratumoral metabolism have not been well studied compared to invasive ductal carcinoma (IDC). We first
Autor:
Takako Yoshioka, Yasuyo Ohi, Yoshihisa Umekita, Yoshiaki Sagara, Yoshiaki Rai, Masakazu Souda, Yoshiatsu Sagara, Yasuaki Sagara, Akihide Tanimoto
Publikováno v:
Histopathology. 59:776-780
Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai Y, Sagara Y, Sagara Y, Sagara Y & Tanimoto A (2011) Histopathology59, 776–780 Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer Aims: Aldehyde dehydrogenase 1 (AL
Autor:
Yasuaki Sagara, Masakazu Souda, Takako Yoshioka, Yoshiatsu Sagara, Yasuyo Ohi, Yoshiaki Sagara, Yoshihisa Umekita, Yoshiaki Rai, Akihide Tanimoto
Publikováno v:
Histopathology. 58:608-616
Yoshioka T, Umekita Y, Ohi Y, Souda M, Sagara Y, Sagara Y, Sagara Y, Rai Y & Tanimoto A (2011) Histopathology58, 608–616 Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up stu
Autor:
Shoichiro Kosha, Yukie Yonehara, Ichiro Iwamoto, Yoshiatsu Sagara, Tsutomu Douchi, Yoshiaki Rai
Publikováno v:
Journal of Obstetrics and Gynaecology Research. 33:696-699
Aim: To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. Methods: Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 ± 9.9 yea
Autor:
Akihide Tanimoto, Masakazu Souda, Shugo Tamada, Yoshihisa Umekita, Yoshiaki Sagara, Yasuyo Ohi, Yoshiaki Rai, Yasuaki Sagara
Publikováno v:
Diagnostic Pathology
Diagnostic Pathology, Vol 6, Iss 1, p 36 (2011)
Diagnostic Pathology, Vol 6, Iss 1, p 36 (2011)
Background Maspin is a unique member of the serine protease inhibitor superfamily and its expression is found in myoepithelial cells of normal mammary glands; therefore, it has been considered to be a myoepithelial marker. We previously reported that
Autor:
Yasuyo Ohi, Tetsuya Takahama, Yoshiaki Rai, Yoshiatsu Sagara, Yoshihisa Umekita, Masakazu Souda, Hiroki Yoshida
Publikováno v:
Pathology international. 56(8)
Expression of estrogen receptor beta (ERbeta) protein in human breast cancer and correlation with clinicopathological factors have been reported by many investigators, but many of them used ERbeta antibodies that react with both wild-type ERbeta (ERb